Sunday, November 1, 2026
Two papers, a psychopharmacology pearl, a psychotherapy pearl and the news.
AI-generated content. This briefing was written by Claude Opus 5.5 and may contain errors. Please verify against the primary source before acting clinically.
| The Paper |
| New research from the psychiatric journals |
Effect of pharmacological treatment of attention-deficit hyperactivity disorder on academic performance: registry-based population study
Lyhmann I, Widding-Havneraas T, Markussen S, Zachrisson HD, Elwert F, Chaulagain A, Bjelland I, Halmøy A, Mykletun A. British Journal of Psychiatry. September 2026.
Norwegian investigators linked national registries for every child aged 5–15 diagnosed with ADHD in 2009–2011 (n = 6,255) and followed them to the end of compulsory schooling. Exposure was cumulative ADHD medication from diagnosis to tenth grade; outcomes were final grades in nine subjects, grade point average, and exemption from assessment.
An ordinary regression showed the familiar small association: medicated children had a GPA about 0.05 points higher (GPA SD 0.94). The key analysis was an instrumental-variable design that used natural variation in clinicians' prescribing practice to strip out residual confounding. That analysis found no causal effect of medication on GPA (−0.01; 95% CI −1.13 to 0.15), on any individual subject, or on exemption rates.
|
In practice
Stimulants reliably improve core symptoms, but this suggests that for children on the margin of treatment — the ones whose prescription depends on which clinician they see — better grades shouldn't be the promised payoff. The instrumental-variable estimate is wide and applies to marginal patients rather than every child, so frame medication around symptoms, function and safety, and pair it with school supports. |
Full text doi:10.1192/bjp.2026.10754
| Outside Psychiatry |
| A general-medicine paper that ends up in our clinic |
Timing of Initiation of Methadone Take-Home Dosing
Hossain MB, Min JE, Kurz M, Seaman S, Bach P, Karim ME, Bruneau J, Socias ME, Gustafson P, Platt R, Greenland S, Nosyk B. JAMA Internal Medicine. September 2026.
In British Columbia, the default for methadone maintenance is daily witnessed dosing at a community pharmacy. Using provincial data from 2010–2022, the authors emulated a target trial comparing no take-home doses with take-homes started at 0–4, 5–12, 13–24 or 25–52 weeks after induction. The analysis covered 9,788 incident users and 31,658 prevalent new users and used clone-censor-weight methods to estimate 78-week mortality and discontinuation (a gap of 5 or more days).
Any take-home dosing beat none. Starting take-homes at 5–12 weeks lowered 78-week all-cause mortality (adjusted risk difference −0.98; 95% CI −1.62 to −0.33) and discontinuation (−5.29; 95% CI −6.82 to −3.76), with similar gains at 13–24 weeks. The benefit faded when take-homes were delayed past 25 weeks, and the pattern held among incident users and across sensitivity analyses.
|
In practice
Daily witnessed dosing is usually defended as a safety measure, but this suggests that withholding take-homes costs retention and lives. If you manage patients on methadone, ask when take-homes are planned and advocate for earlier ones once the patient is clinically stable. Retention on agonist therapy is the outcome that protects against overdose. |
Full text doi:10.1001/jamainternmed.2026.3904
| Past the Boards |
| One advanced clinical point, usually pharmacology |
Guanfacine ER rides on CYP3A4, so an inducer can erase it and an azole can triple it
Extended-release guanfacine is cleared mainly by CYP3A4, which makes it one of the more interaction-prone ADHD drugs. In the labeling studies, ketoconazole raised guanfacine exposure about threefold, and rifampin cut it by about 70%. The label therefore advises halving the dose with a strong 3A4 inhibitor and allowing up to double the dose with a strong inducer. Doses should be readjusted when the interacting drug stops.
In psychiatric patients, the inducers to watch for are carbamazepine, phenytoin, rifampin and St John's wort. On the inhibitor side, look for clarithromycin, azole antifungals and some HIV regimens. A child whose guanfacine stopped working after carbamazepine was added doesn't need a third ADHD drug. Neither does a teenager who became sedated and bradycardic on a course of clarithromycin.
The same alpha-2A pharmacology explains the discontinuation rule. Stopping abruptly can cause rebound hypertension, so taper by no more than 1 mg every 3–7 days. This matters most when an interacting drug has already pushed levels up.
| In the Room |
| A psychotherapy technique, shown in a vignette |
In TFP, confront the contradiction the patient isn't bothered by
In borderline organization, the problem is often not that the patient lacks information. Contradictory views of the same person sit side by side in awareness, and neither affects the other. Kernberg called this primitive denial, a product of splitting: the patient can report both views calmly because they are kept emotionally apart. Interpreting why the split exists is premature at this stage, because there is not yet a shared view that a split is present.
TFP's confrontation is the step in between. After clarification has pinned down exactly what the patient means, confrontation tactfully places the two incompatible elements side by side, here and now, and invites curiosity about how they coexist. It is an observation, not an accusation. Its job is to make the separation itself noticeable and a little uncomfortable. Only then does an interpretation of its purpose — usually protecting an idealized relationship from aggression — have something to land on.
|
Vignette
A 26-year-old woman in her fourteenth session calls her mother "my best friend, the only one who gets me." Ten minutes later she says, without any change in tone, that her mother hasn't called once since her hospitalization — "which is fine, she's busy." The therapist first clarifies how she knows her mother is busy, then confronts: "I notice two things side by side today. Your mother is the one person who truly gets you, and she hasn't called since the hospital. You tell me both, and neither seems to touch the other. What do you make of that?" The patient bristles: "You're trying to make me hate her." The therapist doesn't retreat or defend the remark. Instead, the therapist takes up what is happening between them: "Right now I seem to have become someone attacking a relationship you need to keep safe. Maybe that's part of why the two pictures have to stay apart." Her reaction has brought the split into the room, and that becomes the next thing to work on. |
| Elsewhere |
| Developments worth knowing about |
| • | California's SB 1119, signed September 10, 2026 and named for Adam Raine, requires chatbot operators to build in mental-health resources, adopt safety plans, limit minors' use and alert parents when a chatbot detects a threat of self-harm. Ask adolescents directly about chatbot use, and expect some disclosures to reach families before they reach you. (source) |
| • | The DEA/HHS fourth extension of telemedicine prescribing flexibilities, published December 31, 2025, expires December 31, 2026. As of late October, no permanent special-registration rule had appeared in the Federal Register. If you prescribe stimulants or benzodiazepines to patients you have never seen in person, plan the in-person visits now. (source) |
| *** |
| That's the five. Go see your first patient. |